Truist Reaffirms Buy on Gilead After HIV Franchise Review, Sets $145 Target
Truist Securities has reiterated a Buy rating on Gilead Sciences (NASDAQ:GILD) and held a $145 price target following an in-depth review of the company’s HIV franchise. The firm cited the franchise as the primary driver of Gilead’s modeled fair value, while also pointing to potential upside from oncology, immunology and other pipeline programs. Mar…